Zhou Dang-Xia, Liu Yun-Xia, Xue Ya-Hong
Pathology Department, Medical School, Xi'an Jiaotong University, Xi'an 710061, China.
Patholog Res Int. 2012;2012:908206. doi: 10.1155/2012/908206. Epub 2012 Feb 23.
The aim of this study was to evaluate CD44v6 protein expression and its prognostic value of CD44v6 in ovarian carcinoma. The expression of CD44v6 was analyzed in 62 patients with ovarian carcinoma by immunohistochemical method. The data obtained were analyzed by univariate and multivariate analyses. The present study clearly demonstrates that tumor tissues from 41 (66.1%) patients showed positive expression with CD44v6. The expression of CD44v6 was significantly correlated with histological type, FIGO stage and histological grade of ovarian carcinomas. Concerning the prognosis, the survival period of patients with CD44v6 positive was shorter than that of patients with CD44v6 negative (36.6% versus 66.7%, 5-year survival, P < 0.05). Univariate analysis showed that CD44v6 expression, histological type, FIGO stage and histological grade were associated with 5-year survival, and CD44v6 expression was associated with histological type, FIGO stage and histological grade and 5-year survival. In multivariate analysis, using the COX-regression model, CD44v6 expression was important prognostic factor. In conclusion, these results suggest that CD44v6 may be related to histological type, FIGO stage and histological grade of ovarian carcinomas, and CD44v6 may be an important molecular marker for poor prognosis in ovarian carcinomas.
本研究旨在评估CD44v6蛋白表达及其在卵巢癌中的预后价值。采用免疫组织化学方法分析62例卵巢癌患者CD44v6的表达情况。对所得数据进行单因素和多因素分析。本研究清楚地表明，41例（66.1%）患者的肿瘤组织CD44v6呈阳性表达。CD44v6的表达与卵巢癌的组织学类型、国际妇产科联盟（FIGO）分期及组织学分级显著相关。关于预后，CD44v6阳性患者的生存期短于CD44v6阴性患者（5年生存率分别为36.6%和66.7%，P<0.05）。单因素分析显示，CD44v6表达、组织学类型、FIGO分期及组织学分级与5年生存率相关，且CD44v6表达与组织学类型、FIGO分期、组织学分级及5年生存率相关。多因素分析采用COX回归模型，结果显示CD44v6表达是重要的预后因素。总之，这些结果提示CD44v6可能与卵巢癌的组织学类型、FIGO分期及组织学分级有关，且CD44v6可能是卵巢癌预后不良的重要分子标志物。
